Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
As of today, Vertex Pharmaceuticals(VRTX) shares are valued at $528.28. The company's market cap stands at 134.6B, with a P/E ratio of 35.58.
As of 2026-11-03, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $528.00 and $569.00. The current price stands at $528.28, placing the stock +0.1% above today's low and -7.2% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 2.37M, compared to an average daily volume of 1.76M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $403.16 at its lowest and $569.00 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $403.16 at its lowest and $569.00 at its peak.
VRTX News
...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported mixed results for the third quarter on Monday. The company posted quarterly earnings of $4.76 per sh...
On its third-quarter 2026 earnings call, held on Nov. 2, 2026, Vertex (VRTX -1.02%) raised its full-year 2026 revenue guidance range to $13.15 billion to $13.25...
Analyst ratings
77%
of 35 ratingsMore VRTX News
Vertex Pharmaceuticals (VRTX -1.02%) grew third-quarter revenue 12% to $3.44 billion, as patients kept moving to its newer cystic fibrosis (CF) drug, Alyftrek....
Technology Vertex Continues Its Buy-Zone Run After Hiking 2026 Sales Guidance Licensing Vertex stock jumped late Monday after the biotech giant reported adjuste...
If you only skimmed the headlines on Vertex Pharmaceuticals this year, you probably saw a gene therapy leader juggling regulatory wins, rising R&D spend, and a...
Vertex Pharmaceuticals Inc. (VRTX) announced an update on their ongoing clinical study. Vertex’s new Phase 1 study takes a close look at how its kidney disease...
has delivered strong long term gains for shareholders, and the question now is whether the current US$529.69 share price is still aligned with the cash flows th...
Vertex Pharmaceuticals (VRTX Quick QuoteVRTX - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.